Perrigo Co. Plc (PRGO)

45.97
NYSE : Health Technology
Prev Close 44.87
Day Low/High 44.73 / 46.08
52 Wk Low/High 36.28 / 95.93
Avg Volume 1.78M
Exchange NYSE
Shares Outstanding 135.86M
Market Cap 6.10B
EPS 0.80
P/E Ratio 50.99
Div & Yield 0.76 (1.71%)
INVESTOR ALERT: Investigation Of Perrigo Company Plc Announced By Law Offices Of Howard G. Smith

INVESTOR ALERT: Investigation Of Perrigo Company Plc Announced By Law Offices Of Howard G. Smith

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) concerning the Company and its officers' possible violations of federal...

Valeant Enlists Former Tyco Exec for More Help With Accounting

Valeant Enlists Former Tyco Exec for More Help With Accounting

The appointment of Sam Eldessouky is the latest move by the Canadian drugmaker to regain its reputation from a financial reporting standpoint.

Perrigo Sells Vitamins Business to IVC

Perrigo Sells Vitamins Business to IVC

The transaction follows a Houlihan Lokey-run sale process for the drugmaker's private-label nutraceuticals unit that was started after Mylan NV's takeover attempt was rebuffed.

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Perrigo Company Plc And A Lead Plaintiff Deadline Of July 18, 2016

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Perrigo Company Plc And A Lead Plaintiff Deadline Of July 18, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Perrigo Company plc ("Perrigo") (NYSE: PRGO) securities...

Looking for Relief From Biotech Pain

A lost leader in Celgene and a Perrigo rumor have put a scare in the charts.

Perrigo (PRGO) Stock Retreats as Takeover Speculation Fades

Perrigo (PRGO) Stock Retreats as Takeover Speculation Fades

Perrigo (PRGO) stock is declining this afternoon after Raymond James contended that there are 'few natural buyers' for the company following yesterday's takeover speculation.

Perrigo Rises Further as Takeover Rumor Swirls

Perrigo Rises Further as Takeover Rumor Swirls

With no outright denial of the story to kill it, Perrigo's share rose further in Tel Aviv overnight on a day-old rumor of a $20 billion takeover deal.

Perrigo (PRGO) Stock Spiked After Report of Takeover

Perrigo (PRGO) Stock Spiked After Report of Takeover

Perrigo (PRGO) stock jumped on Tuesday after a report said the company is near an agreement to be acquired by a U.K.-based company for $20 billion.

Valeant Tries to Fix 'Speed Bumps' in Walgreens Deal

Valeant Tries to Fix 'Speed Bumps' in Walgreens Deal

Papa is set to meet with Walgreens management in hopes of ironing out 'speed bumps.'

Valeant, Walgreens CEOs to Tackle 'Speed Bumps'

Papa is set to meet with Walgreens management in hopes of ironing out "speed bumps."

INVESTOR NOTICE: Khang & Khang LLP Announces An Investigation Of Claims Against Perrigo Company Plc And Advises Investors To Contact The Firm

INVESTOR NOTICE: Khang & Khang LLP Announces An Investigation Of Claims Against Perrigo Company Plc And Advises Investors To Contact The Firm

Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO).

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Claims Against Perrigo Company Plc And Advises Investors To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Claims Against Perrigo Company Plc And Advises Investors To Contact The Firm

Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO).

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Perrigo Company Plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Perrigo Company Plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

Endo Could Be the Next Activist Target in Generics

Problems with mesh products and high leverage might scare away a potential buyer. 

Trade-Ideas: Perrigo (PRGO) Is Today's Post-Market Leader Stock

Trade-Ideas: Perrigo (PRGO) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Perrigo (PRGO) as a post-market leader candidate

Valeant 'Received Bid Proposal' From Takeda, TPG

Valeant 'Received Bid Proposal' From Takeda, TPG

The proposal came before former Perrigo boss Papa was installed at the helm of the troubled drugs maker.

Valeant Works to Restore Accounting Reputation

Valeant Works to Restore Accounting Reputation

Former Tyco International executive Sam Eldessouky will take on the role of controller at the the embattled pharmaceutical company at the end of the month.

Valeant Filing: CEO to Earn $1.5M, More if He Meets Goals

Valeant Filing: CEO to Earn $1.5M, More if He Meets Goals

Valeant is working to rebrand itself and it's starting with paying CEO Joe Papa less than his predecessor.

Valeant to Evaluate Sales of Noncore Assets

Valeant to Evaluate Sales of Noncore Assets

Newly appointed CEO Joseph Papa says at the UBS Global Healthcare Conference that the drugmaker will look to pare its debt load through divestitures.

Investors Comforted as Perrigo Sticks to Forecast

Investors Comforted as Perrigo Sticks to Forecast

As the pharma company's investors remain in "show me mode" with a new CEO at the helm, its maintained guidance may have offset revised earning results.

Monsanto, Amazon and Apple: Doug Kass' Views

Monsanto, Amazon and Apple: Doug Kass' Views

Doug Kass shares his thoughts on shorting financials, and wonders if it will be a Monsanto merger Monday.

Papa's New Bag; Sears About to Become a Swan: Best of Kass

Papa's New Bag; Sears About to Become a Swan: Best of Kass

In highlights from this week's trading diary and posts, Kass discusses Joseph Papa's new gig at Valeant and how Sears is about to become a swan.

Perrigo (PRGO) Stock Price Target Reduced at Leerink

Perrigo (PRGO) Stock Price Target Reduced at Leerink

Perrigo’s (PRGO) new management faces problems at the pharmaceutical company that may not be easily fixed, according to Leerink analysts.

Mylan Tacks On Another Generics Company on the Cheap

Mylan Tacks On Another Generics Company on the Cheap

The company is expanding into the generics drug business.

Pre-Market Laggard: Perrigo (PRGO)

Pre-Market Laggard: Perrigo (PRGO)

Trade-Ideas LLC identified Perrigo (PRGO) as a pre-market laggard candidate

Valeant Whipsawed by Criticism Over Drug Prices and New Leadership

The drugmaker's quest to rebrand itself as a patient-first company is foundering over renewed controversy over drug pricing.

New Regime at Perrigo Provides Reason to Invest

New Regime at Perrigo Provides Reason to Invest

To investors' relief, Perrigo's new leadership reaffirmed the pharmaceuticals company's 2016 calendar outlook on Thursday.

Teva Should Break Out of Droopy Drug Pack

Teva Should Break Out of Droopy Drug Pack

Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.

What to Look For When Perrigo (PRGO) Reports Q1 Results

What to Look For When Perrigo (PRGO) Reports Q1 Results

Perrigo (PRGO) is scheduled to release its 2016 first quarter earnings on Thursday before the market open.

TheStreet Quant Rating: D+ (Sell)